Login to Your Account

Clinic Roundup

Tuesday, December 13, 2011

• Soligenix Inc., of Princeton, N.J., published data from an investigator-initiated Phase II trial of orBec (oral beclomethasone dipropionate) showing the drug was well tolerated but did not achieve statistical significance in reducing graft-vs.-host disease (GVHD) following hematopoietic cell transplantation, as previously reported. The data were published in Biology of Blood and Marrow Transplantation. Soligenix halted a Phase III GVHD trial in September after an interim analysis showed it was unlikely to meet its endpoint.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription